Breast Cancer Update, Issue 2, 2018


BCU218

Interview with Harold J Burstein, MD, PhD

Track 1: Case: A 57-year-old woman presents with ER-positive, PR-negative, HER2-positive metastatic breast cancer (mBC)
Track 2: APHINITY: Results of a Phase III study evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for patients with HER2-positive early BC
Track 3: APT trial: Results after a 7-year follow-up of adjuvant paclitaxel and trastuzumab in patients with small, node-negative, HER2-positive BC
Track 4: Postneoadjuvant therapy for patients with residual BC
Track 5: CREATE-X: A Phase III study of adjuvant capecitabine for HER2-negative residual invasive disease after preoperative chemotherapy
Track 6: Deescalating and escalating treatments for early-stage BC based on traditional risk factors
Track 7: PALLAS Phase III trial of standard adjuvant endocrine therapy with or without palbociclib for ER-positive, HER2-negative early BC
Track 8: Use of CDK4/6 inhibitors for patients with ER-positive, HER2-positive BC
Track 9: Benefits of systemic chemotherapy with anti-HER2 therapy in ER-negative, HER2-positive BC
Track 10: Results of the Phase III ExteNET study: Neratinib after trastuzumab-based adjuvant therapy for HER2-positive BC
Track 11: Assessment of residual risk of recurrence in patients with HER2-positive BC after adjuvant therapy
Track 12: Management of neratinib-associated gastrointestinal toxicity; risk-benefit ratio
Track 13: Use of neratinib in HER2-positive BC with brain metastases
Track 14: Delayed use of lapatinib in patients not receiving adjuvant trastuzumab
Track 15: Case: A 56-year-old woman with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene assay Recurrence Score® of 16
Track 16: Genomic assay selection in patients with ER-positive, HER2-negative disease
Track 17: Case: A 63-year-old woman with heavily pretreated ER-positive mBC now considering CDK4/6 inhibitor therapy
Track 18: Activity of CDK4/6 inhibitors alone or in combination with endocrine therapy for ER-positive mBC
Track 19: Comparison of CDK4/6 inhibitors’ efficacy and tolerability
Track 20: Potential role of biomarkers and treatment duration in CDK4/6 inhibitor therapy
Track 21: Case: A 48-year-old woman with advanced-stage, poorly differentiated, triple-negative BC (TNBC) and a BRCA1 mutation receives olaparib on the Phase III OlympiAD trial
Track 22: Activity and tolerability of olaparib
Track 23: OlympiAD: Olaparib for patients with mBC and a germline BRCA mutation
Track 24: Comparison of PARP inhibitors to standard chemotherapy for advanced BRCA-associated BC
Track 25: Clinical experience with PARP inhibitors
Track 26: Case: A 61-year-old woman with a history of early-stage BC presents with triple-negative neuroendocrine carcinoma within the breast
Track 27: Systemic targeted therapy for neuroendocrine tumors with a lutetium radiolabeled agent

Interview with Angelo Di Leo, MD, PhD

Track 1: Case: A 57-year-old postmenopausal woman who received 5 years of adjuvant anastrozole presents with multiple lung metastases
Track 2: Use of adjuvant chemotherapy based on genomic risk assessment
Track 3: Activity of a CDK4/6 inhibitor alone or in combination with an aromatase inhibitor for patients with ER-positive mBC
Track 4: Similarities and differences among the side-effect profiles of CDK4/6 inhibitors
Track 5: Therapeutic options for patients with ER-positive mBC after disease progression on a CDK4/6 inhibitor
Track 6: Management of everolimus-associated mucositis and pneumonitis
Track 7: Ongoing trials investigating CDK4/6 inhibitors in the neoadjuvant and adjuvant settings
Track 8: Case: A 41-year-old premenopausal woman with progressive BRCA1 mutation-positive TNBC and multiple liver metastases
Track 9: Perspective on the use of bevacizumab for mTNBC
Track 10: Use of eribulin mesylate as late-line therapy for mBC
Track 11: OlympiAD: Results of a Phase III trial of olaparib monotherapy versus chemotherapy for patients with HER2-negative mBC and germline BRCA mutations
Track 12: Design limitations of the OlympiAD trial; sequencing of olaparib
Track 13: Tolerability of olaparib
Track 14: Effect of mBC diagnosis on family life and children
Track 15: Case: A 47-year-old premenopausal woman presents with an ER-negative, HER2-positive, node-positive Grade III IDC and vascular invasion
Track 16: Potential role of pertuzumab as a component of adjuvant therapy for patients with early-stage HER2-positive BC
Track 17: Estimating risk of recurrence in patients with BC
Track 18: Balancing magnitude of benefit and toxicity profiles of adjuvant pertuzumab and/or postadjuvant neratinib for early-stage HER2-positive BC
Track 19: Case: A 48-year-old premenopausal woman with an ER-positive, HER2-negative Grade II IDC and limited nodal involvement
Track 20: Comparison of available multigene assays
Track 21: Potential overestimation of disease relapse risk with genomic assays
Track 22: Case: A 55-year-old woman with ER-positive, node-positive BC receives CMF to avoid chemotherapy-related alopecia
 
FACULTY
 
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
 
Angelo Di Leo, MD, PhD
Head of the Sandro Pitigliani
Department of Medical Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida